These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32921403)

  • 1. Enhanced recovery after surgery is safe for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Martin RC; Marshall BM; Philips P; Egger M; McMasters KM; Scoggins CR
    Am J Surg; 2020 Dec; 220(6):1428-1432. PubMed ID: 32921403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Postoperative Pain Management Outcomes After Implementation of Enhanced Recovery After Surgery (ERAS) Protocol for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC).
    Yue TM; Sun BJ; Xu N; Ohkuma R; Fowler C; Lee B
    Ann Surg Oncol; 2024 Jun; 31(6):3769-3777. PubMed ID: 38466484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Successful Implementation of an Enhanced Recovery After Surgery Protocol for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Sun BJ; Yue TM; Xu N; Fowler C; Lee B
    Ann Surg Oncol; 2023 Dec; 30(13):8156-8165. PubMed ID: 37684372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Enhanced Recovery After Following a Surgical Protocol for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Duzgun O
    Med Arch; 2019 Oct; 73(5):331-337. PubMed ID: 31819307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive Surgery and HIPEC in an Enhanced Recovery After Surgery Program: A Feasibility Study.
    Lu PW; Fields AC; Shabat G; Bleday R; Goldberg JE; Irani J; Stopfkuchen-Evans M; Melnitchouk N
    J Surg Res; 2020 Mar; 247():59-65. PubMed ID: 31767280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoption of an Enhanced Recovery After Surgery Protocol Increases Cost of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy and Does not Improve Outcomes.
    Ciftci Y; Radomski SN; Johnson BA; Johnston FM; Greer JB
    Ann Surg Oncol; 2024 Aug; 31(8):5390-5399. PubMed ID: 38777898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of an Enhanced Recovery After Surgery (ERAS) Program is Associated with Improved Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Webb C; Day R; Velazco CS; Pockaj BA; Gray RJ; Stucky CC; Young-Fadok T; Wasif N
    Ann Surg Oncol; 2020 Jan; 27(1):303-312. PubMed ID: 31605328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Enhanced Recovery After Surgery on Postoperative Outcomes for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    White B; Dahdaleh F; Naffouje SA; Kothari N; Berg J; Wiemann W; Salti GI
    Ann Surg Oncol; 2021 Sep; 28(9):5265-5272. PubMed ID: 33469794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations - Part II: Postoperative management and special considerations.
    Hübner M; Kusamura S; Villeneuve L; Al-Niaimi A; Alyami M; Balonov K; Bell J; Bristow R; Guiral DC; Fagotti A; Falcão LFR; Glehen O; Lambert L; Mack L; Muenster T; Piso P; Pocard M; Rau B; Sgarbura O; Somashekhar SP; Wadhwa A; Altman A; Fawcett W; Veerapong J; Nelson G
    Eur J Surg Oncol; 2020 Dec; 46(12):2311-2323. PubMed ID: 32826114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 11. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management.
    Hübner M; Kusamura S; Villeneuve L; Al-Niaimi A; Alyami M; Balonov K; Bell J; Bristow R; Guiral DC; Fagotti A; Falcão LFR; Glehen O; Lambert L; Mack L; Muenster T; Piso P; Pocard M; Rau B; Sgarbura O; Somashekhar SP; Wadhwa A; Altman A; Fawcett W; Veerapong J; Nelson G
    Eur J Surg Oncol; 2020 Dec; 46(12):2292-2310. PubMed ID: 32873454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis.
    Bekhor E; Carr J; Hofstedt M; Sullivan B; Solomon D; Leigh N; Bolton N; Golas B; Sarpel U; Labow D; Magge D
    Ann Surg Oncol; 2020 May; 27(5):1448-1455. PubMed ID: 31873928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
    Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy vs. cytoreductive surgery alone for intrahepatic cholangiocarcinoma with peritoneal metastases: A retrospective cohort study.
    Feng F; Gao Q; Wu Y; Liu C; Yu Y; Li B; Chu K; Yi B; Cheng Q; Jiang X
    Eur J Surg Oncol; 2021 Sep; 47(9):2363-2368. PubMed ID: 34119376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term outcomes in older patients with peritoneal malignancy treated with cytoreductive surgery and HIPEC: Experience with 245 patients from a national centre.
    Keyes AM; Kelly ME; McInerney N; Khan MF; Bolger JC; McCormack E; Grundy J; McCormack O; MacHale J; Conneely J; Brennan D; Cahill R; Shields C; Moran B; Mulsow J
    Eur J Surg Oncol; 2021 Sep; 47(9):2358-2362. PubMed ID: 33895028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
    Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
    J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
    Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and benefits of an enhanced recovery after surgery protocol for patients undergoing cytoreductive surgery and heated intraperitoneal chemotharpy: A single institution experience.
    Siddharthan R; Dewey E; Billingsley K; Gilbert E; Tsikitis VL
    Am J Surg; 2020 Jun; 219(6):1073-1075. PubMed ID: 31253353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
    Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
    BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.